Elexacaftor-VX-445-DataSheet-生命科學試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemEElexacaftorCat.No.:HY-111772CASNo.:2216712-66-0Synonyms:VX-445分?式:C??H??F?N?O?S分?量:597.65作?靶點:CFTR;Autophagy作?通路:MembraneTransporter/IonChannel;Autophagy儲存?式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實驗DMSO:125mg/mL(209.15mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制備儲備液1mM1.6732mL8.3661mL16.7322mL5mM0.3346mL1.6732mL3.3464mL10mM0.1673mL0.8366mL1.6732mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；?旦配成溶液，請分裝保存，避免反復凍融造成的產(chǎn)品失效。儲備液的保存?式和期限：-80°C,6months;-20°C,1month。-80°C儲存時，請在6個?內(nèi)使?，-20°C儲存時，請在1個?內(nèi)使?。體內(nèi)實驗請根據(jù)您的實驗動物和給藥?式選擇適當?shù)娜芙?案。以下溶解?案都請先按照InVitro?式配制澄的儲備液，再依次添加助溶劑：(為保證實驗結(jié)果的可靠性，澄的儲備液可以根據(jù)儲存條件，適當保存；體內(nèi)實驗的?作液，建議您現(xiàn)?現(xiàn)配，當天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的?式助溶)1.請依序添加每種溶劑：10%DMSO>>40%PEG300>>5%Tween-80>>45%saline1/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemESolubility:≥2.08mg/mL(3.48mM);Clearsolution2.請依序添加每種溶劑：10%DMSO>>90%cornoilSolubility:≥2.08mg/mL(3.48mM);ClearsolutionBIOLOGICALACTIVITY?物活性Elexacaftor(VX-445,Compound1)?種囊性纖維化跨膜電導調(diào)節(jié)因?(CFTR)校正劑。Elexacaftor(VX-445,Compound1)促進CFTR的加?和轉(zhuǎn)運，增加細胞表CFTR的數(shù)量。IC50&TargetCFTR[1].體外研究Elexacaftor(VX-445)isanext-generationcysticfibrosistransmembraneconductanceregulator(CFTR)correctordesignedtorestorePhe508delCFTRproteinfunction.Elexacaftor(VX-445)hasthepotentialtotreatcysticfibrosis.VX-445-Tezacaftor-VX-770significantlyimprovesPhe508delCFTRproteinprocessing,trafficking,andchloridetransporttoagreaterextentthananytwooftheseagentsindualcombination[2].戶使?本產(chǎn)品發(fā)表的科研?獻?AmJRespirCritCareMed.2021Aug11.?JClinInvest.2021Aug16;131(16):e150398.?JCIInsight.2020Sep17;5(18):e139983.?IntJMolSci.2022,23(1),24.?IntJMolSci.2021,22(6),3063.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].AlexanderRussellAbela,etal.MODULATOROFTHECYSTICFIBROSISTRANSMEMBRANECONDUCTANCEREGULATOR,PHARMACEUTICALCOMPOSITIONS,METHODSOFTREATMENT,ANDPROCESSFORMAKINGTHEMODULATOR.US20180162839A1.[2].KeatingD,etal.VX-445-Tezacaftor-VX-770inPatientswithCysticFibrosisandOneorTwoPhe508delAlleles.NEnglJMed.2018Oct25;379(17):1612-1620.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresear